Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.73 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.73 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832567 | 1.00 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL832040 | 0.95 | HDAC1 (0.79) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL832039 | 0.95 | HDAC1 (0.79) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL830619 | 0.89 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL830620 | 0.89 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL12560505 | 0.89 | HDAC1 (0.77) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL832370 | 0.88 | HDAC1 (0.77) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL832371 | 0.88 | HDAC1 (0.77) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL3308154 | 0.86 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL833341 | 0.86 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | claimed |
| EP-1937650-B1 | HETEROCYCLIC COMPOUNDS | S BIO PTE LTD (SG) | 2011-06-15 | — | — | EP | claimed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | claimed |
| EP-2131840-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*Bio Pte Ltd (SG) | 2009-12-16 | — | — | EP | claimed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | claimed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | claimed |
| EP-3662911-A1 | COMBINATION OF AZACITIDINE AND PRACINOSTAT TO TREAT MYELODYSPLASTIC SYNDROME (MDS) | MEI Pharma, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-2914254-B1 | COMBINATION THERAPIES TO TREAT CHEMORESISTANT CANCERS | MEI PHARMA INC (US) | 2020-01-08 | — | — | EP | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| EP-2131840-B1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| US-20150258068-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150258068-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2015-09-17 | — | — | US | disclosed |
| EP-1937650-B1 | HETEROCYCLIC COMPOUNDS | S BIO PTE LTD (SG) | 2011-06-15 | — | — | EP | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| EP-2131840-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*Bio Pte Ltd (SG) | 2009-12-16 | — | — | EP | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC8 4/4885HDAC3 2/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | HDAC1 163/4885HDAC8 172/4885HDAC3 558/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | HDAC1 163/4885HDAC8 172/4885HDAC3 558/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | HDAC1 47/4885HDAC8 7/4885HDAC3 29/4885 |
| US-20150258068-A1 | COMBINATION THERAPIES | HDAC1, HDAC8, HDAC5 | HDAC1 1/4885HDAC8 2/4885HDAC3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.